Novo Nordisk A/S (NVO)
| Market Cap | 399.00B |
| Revenue (ttm) | 40.31B |
| Net Income (ttm) | 14.02B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.14 |
| PE Ratio | 28.46 |
| Forward PE | 23.22 |
| Dividend | $1.30 (1.44%) |
| Ex-Dividend Date | Mar 31, 2025 |
| Volume | 3,336,363 |
| Open | 90.66 |
| Previous Close | 90.65 |
| Day's Range | 89.43 - 90.74 |
| 52-Week Range | 77.82 - 148.15 |
| Beta | 0.19 |
| Analysts | Strong Buy |
| Price Target | 141.67 (+57.24%) |
| Earnings Date | Feb 5, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $141.67, which is an increase of 57.24% from the latest price.
News
Novo Nordisk (NVO) Hit with Investor Lawsuit Over CagriSema Obesity Drug - Hagens Berman
SAN FRANCISCO , Feb. 28, 2025 /PRNewswire/ -- Novo Nordisk A/S (NYSE: NVO) is embroiled in a class-action lawsuit filed by investors who claim they were misled about the future of its experimental obe...
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 27 February 2025 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 27 March 2024 at 14.00 (CET) The Annual General Meeting is held as a partially electronic...
6 Stocks to Buy as European Markets Soar
Stocks in the United States are off to a choppy but positive start to the year, but the biggest story in markets so far in 2025 has been strength out of Europe.
Novo Nordisk's stock is rallying as Hims & Hers' stock falters. An Ozempic alternative won't be available for long.
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won't be selling it for much longer.
Novo Nordisk (NVO) Hit with Investor Lawsuit Over CagriSema Obesity Drug – Hagens Berman
SAN FRANCISCO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk A/S (NYSE: NVO) is embroiled in a class-action lawsuit filed by investors who claim they were misled about the future of its experimental ...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo Nordisk To Contact Him Directly To Discuss Their Options If you purchased or acq...
Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
The long-running U.S. shortage of Novo Nordisk's blockbuster weight loss injection Wegovy and diabetes treatment Ozempic is resolved after more than two years, the Food and Drug Administration said. T...
Investors in Novo Nordisk A/S Should Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights – NVO
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
Novo Nordisk Prices In Too Few New Patients For GLP-1 Currently
Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. Adding 5m GLP-1 patients at slightly lower prices or 21m at LLY price levels both lead to 20...
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Novo Nordisk is doing exceptionally well in the face of the challenges posed by Eli Lilly. So, sales of Ozempic and Wegovy amounted to DKK 53.7 billion in the fourth quarter of 2024, increasing by 35....
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo Nordisk To Contact Him Directly To Discuss Their Options
A Rip Van Winkle Portfolio: Invest In These Companies And Forget You Did It
The Rip Van Winkle portfolio advocates for long-term, buy-and-hold investing in companies with competitive advantages, reasonable valuations, and strong financial performance. Alphabet, Meta, and Alib...
Novo Nordisk alleges fraud after $1.3 billion deal to buy hypertension drug from KBP Biosciences
Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as the Danish drugmaker says it was misled when it bought a new hypertension dru...
Novo Nordisk: Dips Like These Come Once Every Few Years
Novo Nordisk: Dips Like These Come Once Every Few Years
Ozempic shows some promise for alcohol use disorder
Novo Nordisk's blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a small trial, researchers reported on Wednesday.
Ozempic's Active Ingredient May Reduce Alcohol Cravings, Study Says
The active ingredient in Ozempic and Wegovy was linked to reduced cravings for drinking alcohol among people with alcohol use disorder, according to a small study published Wednesday in the journal JA...
Popular weight-loss drug helps to reduce alcohol consumption and smoking, new study finds
Ozempic and other semaglutide drugs help people reduce their drinking, a new study has found.
MoneyShow's Best Investment Ideas For 2025: Part 10
MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with tur...
Is Novo Nordisk's Bottom Here? Oversold Status Below 10Y P/E Lows
Novo Nordisk's drastic selloff may be attributed to the management overpromising CagriSema's 25% weight loss target along with the decelerating top-line growth trend. The company now faces numerous he...
Novo Nordisk: 2024 Earnings Review
Novo Nordisk's 2024 earnings exceeded estimates, with 25% revenue growth and strong performance in diabetes, obesity, and rare disease segments. The market overreacted to CagriSema trial results, caus...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 7 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo ...
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds
Final Trade: UPST, MTCH, NVO, C
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line with expectations. Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply impro...